US Markets
GIL

Hong Kong gives conditional greenlight to Gilead COVID-19 drug containing Remdesivir

Credit: REUTERS/MIKE BLAKE

A Gilead Sciences medicine containing Remdesivir has received a conditional greenlight to be used to curb the coronavirus pandemic, Hong Kong officials said on Friday.

HONG KONG, July 17 (Reuters) - A Gilead Sciences GIL.O medicine containing Remdesivir has received a conditional greenlight to be used to curb the coronavirus pandemic, Hong Kong officials said on Friday.

The Hong Kong unit of the California-based drugmaker has to continue to submit additional data on the safety, effectiveness and quality of Veklury, which contains Remdesivir, the Drug Office of Department of Health said on its website.

Remdesivir, which helped shorten hospital recovery times in a U.S. clinical trial, has been added to several countries' list of treatments against the disease that has killed over half a million people globally.

(Reporting by Twinnie Siu Hong Kong, Roxanne Liu in Beijing; Editing by Catherine Evans)

((hongkong.newsroom@thomsonreuters.com; (8610)6627-1277; Reuters Messaging: roxanne.liu@thomsonreuters.com))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GIL GILD

Latest US Markets Videos

Test Video TOPIC US market

Nov 24, 2021

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More